Response to 13 cis retinoic acid in metatstatic neuroblastoma

Authors

  • R. Arun Kumar Department of Medical Oncology, Institute of Obstetrics and Gynaecology, Egmore, Madras Medical College, Tamil Nadu
  • S. Lakshmi Narasimhan Department of Medical Oncology, Institute of Obstetrics and Gynaecology, Egmore, Madras Medical College, Tamil Nadu
  • J. Muthukumaran Department of Paediatric Surgery, Institute of Child Health, Madras Medical College, Egmore, Chennai, Tamil Nadu

DOI:

https://doi.org/10.18203/2349-3291.ijcp20163703

Keywords:

Complete response, Neuroblastoma, Retinoid therapy

Abstract

Neuroblastoma is the most common extra cranial solid tumour of childhood, with 5 year survival rate of 40%-50% in high risk group. Surgery, chemotherapy, radiotherapy, high dose chemotherapy with stem cell transplant and retinoid therapy are treatment options for neuroblastoma. Here we present a 5 year female child presenting with abdominal pain for 1 month and abdominal distension for 3 weeks, and underwent biopsy after necessary investigations, and diagnosed to have high risk neuroblastoma and treated with multiple lines of chemotherapy and attained complete response after retinoid therapy. The case is presented because of complete response achieved with retinoid therapy with tolerable side effects.

References

Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341(16):1165-73.

Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003;197(1-2):185-92.

Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30(26):3264-70.

Yu AL, Gilman AL, Ozkaynak MF. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma children's oncology group. N Engl J Med. 2010;363(14):1324-34.

Maris JM, Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202-11.

Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist. 2003;8(3):278-92.

Pappo AS, Navid F, Brennan RC, Krasin MJ, Andrew M, Wayne L. Furman. In : Solid tumours in Childhood. De Vita, Hellman and Rosenberg’s Cancer-Principles and Practice of Oncology 10th Edition. Philadelphia PA: Wolter Kluver Health. 2015:1465-74.

Arora RS, Eden T, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer. 2009;46:264-73.

Downloads

Published

2016-12-22